{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:39:56Z","timestamp":1782477596471,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":9,"publisher":"Springer US","isbn-type":[{"value":"9781071629024","type":"print"},{"value":"9781071629031","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2903-1_9","type":"book-chapter","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T15:02:51Z","timestamp":1676559771000},"page":"109-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gyrolab Immunoassays: Miniaturization, Automation, and Integration into a Rapid Workflow"],"prefix":"10.1007","author":[{"given":"Johan","family":"Engstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"9_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/0019-2791(71)90454-X","volume":"8","author":"E Engvall","year":"1971","unstructured":"Engvall E, Perlmann P (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 8:871\u2013874","journal-title":"Immunochemistry"},{"key":"9_CR2","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1021\/ac061692y","volume":"79","author":"P Andersson","year":"2007","unstructured":"Andersson P, Jesson G, Kylberg G et al (2007) Parallel nl microfluidic analysis system. Anal Chem 79:4022\u20134030","journal-title":"Anal Chem"},{"key":"9_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes DJAR, Troc\u00f3niz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58:835\u2013857","journal-title":"Clin Pharmacokinet"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"T Hansel","year":"2010","unstructured":"Hansel T, Kropshofer H, Singer T et al (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325\u2013338","journal-title":"Nat Rev Drug Discov"},{"key":"9_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC et al (2019) Cytokine release syndrome: current perspectives. Immunotargets Ther 8:43\u201352","journal-title":"Immunotargets Ther"},{"key":"9_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H et al (2019) Cytokine Release Syndrome: Current Perspectives. ImmunoTargets and Therapy 8:43\u201352","journal-title":"ImmunoTargets and Therapy"},{"key":"9_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40495-019-00193-6","volume":"5","author":"J Punnonen","year":"2019","unstructured":"Punnonen J, Rosen D, Zuniga L et al (2019) Cytokine therapeutics in cancer immunotherapy: design and development. Curr Pharmacol Rep 5:377\u2013390","journal-title":"Curr Pharmacol Rep"},{"issue":"1","key":"9_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","volume":"7","author":"EI Buchbinder","year":"2019","unstructured":"Buchbinder EI, Dutcher JP, Daniels GA et al (2019) Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer 7(1):49","journal-title":"J Immunother Cancer"},{"key":"9_CR9","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","volume":"10","author":"A Diab","year":"2020","unstructured":"Diab A, Tannir NM, Bentebibel SE et al (2020) Bempegaldesleukin (NKTR-214) plus Nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov 10:1158\u20131173. Cytokine storms: understanding COVID-19. Nilam Mangalmurti and Christopher A. Hunter. Immunity 53, July 14, 2020","journal-title":"Cancer Discov"}],"container-title":["Methods in Molecular Biology","ELISA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2903-1_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T15:03:28Z","timestamp":1676559808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2903-1_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071629024","9781071629031"],"references-count":9,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2903-1_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"17 February 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}